BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25594072)

  • 41. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
    Le Page C; Rahimi K; Rodrigues M; Heinzelmann-Schwarz V; Recio N; Tommasi S; Bataillon G; Portelance L; Golmard L; Meunier L; Tonin PN; Gotlieb W; Yasmeen A; Ray-Coquard I; Labidi-Galy SI; Provencher D; Mes-Masson AM
    Gynecol Oncol; 2020 Feb; 156(2):377-386. PubMed ID: 31753525
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Distinct allelic loss patterns in papillary serous carcinoma of the peritoneum.
    Huang LW; Garrett AP; Schorge JO; Muto MG; Bell DA; Welch WR; Berkowitz RS; Mok SC
    Am J Clin Pathol; 2000 Jul; 114(1):93-9. PubMed ID: 10884804
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison Of Early-Stage High-Grade Serous Primary Fallopian Tube Cancers and Epithelial Ovarian Cancers: A Multicenter Study.
    Gungorduk K; Ozdemir A; Selcuk I; Telli E; Şahin Ö; Toptaş T; Akman L; Güzel AB; Taşkın S; Öge T; Güngördük Ö; Gokçü M; Gungor T; Yaşar L; Terek MC; Ozan H; Ozsaran A; Sancı M; Vardar MA; Meydanlı MM; Yalçın ÖT; Ortac F; Özalp S
    Oncol Res Treat; 2017; 40(4):203-206. PubMed ID: 28376498
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.
    Le Page C; Rahimi K; Köbel M; Tonin PN; Meunier L; Portelance L; Bernard M; Nelson BH; Bernardini MQ; Bartlett JMS; Bachvarov D; Gotlieb WH; Gilks B; McAlpine JN; Nachtigal MW; Piché A; Watson PH; Vanderhyden B; Huntsman DG; Provencher DM; Mes-Masson AM
    BMC Cancer; 2018 Mar; 18(1):347. PubMed ID: 29587661
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
    Cho D; Park H; Park SH; Kim K; Chung M; Moon W; Kang M; Jang K
    J Ovarian Res; 2015 Feb; 8():2. PubMed ID: 25823848
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.
    Rubin SC; Benjamin I; Behbakht K; Takahashi H; Morgan MA; LiVolsi VA; Berchuck A; Muto MG; Garber JE; Weber BL; Lynch HT; Boyd J
    N Engl J Med; 1996 Nov; 335(19):1413-6. PubMed ID: 8875917
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells.
    Chodankar R; Kwang S; Sangiorgi F; Hong H; Yen HY; Deng C; Pike MC; Shuler CF; Maxson R; Dubeau L
    Curr Biol; 2005 Mar; 15(6):561-5. PubMed ID: 15797026
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Whence High-Grade Serous Ovarian Cancer.
    Kohn EC; Ivy SP
    Am Soc Clin Oncol Educ Book; 2017; 37():443-448. PubMed ID: 28561656
    [TBL] [Abstract][Full Text] [Related]  

  • 50. No association between BRCA1 immunohistochemical expression and tumor grade, stage or overall survival in platinum-treated epithelial ovarian cancer patients.
    Shawky Ael-A; El-Hafez AA; El-Tantawy D; Hamdy R
    Asian Pac J Cancer Prev; 2014; 15(10):4275-9. PubMed ID: 24935384
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hereditary ovarian cancer.
    Prat J; Ribé A; Gallardo A
    Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BRCA1 germline mutations in women with uterine serous papillary carcinoma.
    Lavie O; Hornreich G; Ben Arie A; Renbaum P; Levy-Lahad E; Beller U
    Obstet Gynecol; 2000 Jul; 96(1):28-32. PubMed ID: 10862837
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
    Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
    [TBL] [Abstract][Full Text] [Related]  

  • 54. BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum.
    Bandera CA; Muto MG; Schorge JO; Berkowitz RS; Rubin SC; Mok SC
    Obstet Gynecol; 1998 Oct; 92(4 Pt 1):596-600. PubMed ID: 9764635
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
    Rauh-Adelmann C; Lau KM; Sabeti N; Long JP; Mok SC; Ho SM
    Mol Carcinog; 2000 Aug; 28(4):236-46. PubMed ID: 10972993
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 57. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation.
    DelloRusso C; Welcsh PL; Wang W; Garcia RL; King MC; Swisher EM
    Mol Cancer Res; 2007 Jan; 5(1):35-45. PubMed ID: 17259345
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer.
    Shen YT; Wang L; Evans JC; Allen C; Piquette-Miller M
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31117198
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Incidence of loss of heterozygosity at p53 and BRCA1 loci in serous surface carcinoma.
    Quezado MM; Moskaluk CA; Bryant B; Mills SE; Merino MJ
    Hum Pathol; 1999 Feb; 30(2):203-7. PubMed ID: 10029450
    [TBL] [Abstract][Full Text] [Related]  

  • 60. AGO Austria recommendations for genetic testing of patients with ovarian cancer.
    Marth C; Hubalek M; Petru E; Polterauer S; Reinthaller A; Schauer C; Scholl-Firon T; Singer CF; Zschocke J; Zeimet AG
    Wien Klin Wochenschr; 2015 Aug; 127(15-16):652-4. PubMed ID: 26109557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.